Shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) have been given a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.

Analysts have set a twelve-month consensus target price of $5.10 for the company and are forecasting that the company will post ($0.19) EPS for the current quarter, according to Zacks. Zacks has also assigned ESSA Pharma an industry rank of 104 out of 265 based on the ratings given to related companies.

A number of research analysts have issued reports on the stock. Dawson James restated a “buy” rating on shares of ESSA Pharma in a research report on Thursday, August 3rd. Bloom Burton restated a “buy” rating on shares of ESSA Pharma in a research report on Thursday, May 18th. ValuEngine downgraded shares of ESSA Pharma from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 7th. Finally, Zacks Investment Research downgraded shares of ESSA Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, May 18th.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/07/zacks-essa-pharma-inc-epix-receives-consensus-recommendation-of-strong-buy-from-brokerages.html.

ESSA Pharma (NASDAQ EPIX) traded up 37.50% on Thursday, hitting $0.44. 1,628,998 shares of the stock traded hands. The stock has a 50-day moving average of $0.34 and a 200-day moving average of $1.44. The firm’s market cap is $12.80 million. ESSA Pharma has a 12-month low of $0.25 and a 12-month high of $3.59.

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.